Denosumab uk patent expiry?

When does the UK patent on Denosumab expire?
The primary UK patent covering the antibody denosumab (filed in 2006 under the European Patent Office) reaches its 20‑year limit in 2026. Data‑exclusivity provisions can extend market protection a few years beyond that point, but the core patent itself lapses that year. [1]

Who owns the UK patent?
The rights are held by Amgen Inc. and its European subsidiaries, the same entities that hold the original patents worldwide. Amgen’s ownership covers the antibody composition, the therapeutic use for osteoporosis and bone‑metastasis prevention, and the formulation used in the Prolia and Xgeva products. [1]

Will biosimilars appear after expiry?
Once the patent expires, other companies can develop biosimilar versions of denosumab. In the UK, the regulatory pathway requires demonstration of comparable efficacy, safety and immunogenicity, but the patent expiration removes the legal barrier that once prevented entry. Several candidates are already in advanced clinical stages, and the first biosimilar could enter the market within a few years after 2026. [1]

How will price be affected?
The end of patent protection typically opens the door for price competition. The NHS has historically negotiated significant discounts for Prolia and Xgeva when patents expired in other territories. If a biosimilar gains approval, the cost of treating osteoporosis and bone‑metastasis patients could fall markedly, potentially freeing budget for other therapies. [1]

Are there other patents protecting the drug in the UK?
Amgen also holds secondary patents covering specific antibody variants, manufacturing processes, and delivery systems. These secondary claims usually run concurrently with the main patent but do not extend the overall exclusivity period beyond the primary 20‑year term. When the main patent expires in 2026, secondary patents typically expire shortly thereafter, allowing full generic entry. [1]

What does this mean for patients and clinicians?
Patients could benefit from lower costs and increased access to denosumab if a biosimilar becomes available. Clinicians will need to stay informed about efficacy data for new entrants to ensure continued treatment quality. The transition period will be managed by the NHS to maintain treatment continuity while integrating any new biosimilar options. [1]

---

Sources
1. https://www.drugpatentwatch.com/denosumab/UK